Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Denifanstat by Sagimet Biosciences for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
Denifanstat is under clinical development by Sagimet Biosciences and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to...
Denifanstat by Sagimet Biosciences for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Denifanstat is under clinical development by Sagimet Biosciences and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...
Denifanstat by Sagimet Biosciences for Liver Cirrhosis: Likelihood of Approval
Denifanstat is under clinical development by Sagimet Biosciences and currently in Phase I for Liver Cirrhosis. According to GlobalData, Phase...
Denifanstat by Sagimet Biosciences for Glioblastoma Multiforme (GBM): Likelihood of Approval
Denifanstat is under clinical development by Sagimet Biosciences and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...